Hikal Limited’s Board of Directors approved the unaudited financial results for the quarter and nine months ended December 31, 2025. The company declared an Interim Dividend of ₹0.20 per equity share (10%) for FY 2025-26. The results also highlighted significant exceptional charges related to new labour codes. The trading window is set to reopen on February 14, 2026.
Financial Performance for Q3 FY2025-26
Hikal Limited announced the outcome of its Board meeting held on February 11, 2026, where the unaudited financial results for the quarter and nine months ending December 31, 2025, were approved. The results, both Standalone and Consolidated, were subject to a modified Limited Review by the Statutory Auditors.
Key Financial Highlights (Standalone)
For the quarter ended December 31, 2025, the Standalone results showed a loss before tax after exceptional items of (₹92 million), compared to a profit before tax of ₹239 million in the corresponding quarter last year. Total income for the quarter stood at ₹4,971 million.
For the nine months ended December 31, 2025, the Standalone loss before tax after exceptional items was (₹867 million), against a profit of ₹555 million in the previous corresponding nine-month period. Earnings Per Share (EPS) for the quarter stood at (₹0.48).
Consolidated Performance
The Consolidated results for the quarter showed a loss before tax after exceptional items of (₹92 million), similar to the standalone figures, with Total Income at ₹4,971 million.
The nine months ended December 31, 2025, reflected a Consolidated loss before tax after exceptional items of (₹866 million). Consolidated EPS for the quarter was (₹0.48).
Interim Dividend Declaration
The Board approved the declaration of an Interim Dividend for the financial year 2025-26 at a rate of 10%, equivalent to ₹0.20 per equity share (Nominal value ₹2/- each). The Record Date for determining entitled shareholders is set for Tuesday, February 17, 2026. The dividend payment is scheduled to be completed on or before Thursday, March 12, 2026.
Exceptional Items and Corporate Matters
A significant factor impacting profitability in the current period was the booking of an Exceptional Item of (₹380 million) in both standalone and consolidated results. This charge is linked to the financial impact assessment resulting from the notification of the four new Labour Codes by the Government of India in November 2025, covering gratuity and compensated absences.
Regarding the previous quarter’s concerns on revenue recognition irregularities, a fact-finding review is currently in progress, and pending its final outcome, no further adjustments have been made to the current results.
Furthermore, note 4 refers to the ongoing uncertainty regarding investigations related to environmental laws, which remains pending before the Hon’ble Supreme Court of India, with no adjustments made to the current financial results for this matter.
Trading Window Update
The trading window for Designated Persons, closed since January 1, 2026, is scheduled to reopen on February 14, 2026. However, a special closure remains in effect for Directors, KMPs, and specified senior management personnel until further communication.
Segment Performance Summary (Standalone)
Segment analysis for the quarter ended December 31, 2025, indicated strong revenue from operations at ₹4,943 million. Segment results showed a profit before tax (before exceptional item) of ₹288 million for Pharmaceuticals and a loss of (₹175 million) for Crop Protection.
The nine months segment revenue reached ₹11,932 million for Pharmaceuticals and ₹4,638 million for Crop Protection. Profit before tax (before exceptional item) for the nine-month period was (₹487 million).
Source: BSE
